Real-World study to track Jivi's bleeding prevention in kids
NCT ID NCT07088458
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study will follow 40 children aged 7 to 12 with hemophilia A who are already prescribed damoctocog alfa pegol (Jivi) to prevent bleeding. Researchers will collect data from routine care, including bleeding episodes and treatment patterns, over two years. The goal is to understand how well the drug works in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- damoctocog alfa pegol (Jivi)
- What this could lead to
- If successful, this study could provide real-world evidence on how well Jivi prevents bleeding episodes in children, helping doctors tailor treatment.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection. It does not test a new drug or compare treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Can a new clotting factor offer better bleed protection for severe hemophilia?
- Do newer hemophilia drugs protect joints better? study aims to find out
- Newborn screening study aims to catch rare diseases at birth
- Could home blood tests transform hemophilia care? study seeks patient views
- New clotting factor shows promise for hemophilia a bleeds